Compare GSK plc (GSK) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vertiv Holdings Co — how do they compare? GSK plc trades at $46.7 (market cap $95.18B), while Vertiv Holdings Co trades at $248 (market cap $94.90B). The key difference: GSK plc and Vertiv Holdings Co are close in size by market cap, and GSK plc pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Vertiv Holdings Co for 39 Days on average.
| GSK | VRT | |
|---|---|---|
Market Cap | $95.18B | $94.90B |
Volume | 5,852,596 | 5,469,277 |
Sector | Health | Industrials |
52-Week High | $61.18 | $376.23 |
52-Week Low | $43.24 | $149.83 |
Typical Hold Time | 93 Days | 39 Days |
Enterprise Value | $115.25B | $95.12B |
Dividend Yield | 3.86% | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 0.13% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 15.1 and EV/EBITDA of 9.0. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for growth beyond upcoming HIV patent expirations.
GSK presents a balanced investment case with solid profitability (29.7% ROE) offset by near-term headwinds. The stock offers value at current levels but faces execution risks from pipeline development and patent cliffs. Analyst sentiment leans cautious with 55% hold ratings, suggesting moderate upside potential with careful risk management required.
Vertiv (VRT) trades at $246.49, down 2.63% amid bearish technical signals but maintains strong fundamental momentum with consistent earnings beats and robust AI-driven data center demand. The stock shows elevated valuation multiples (P/E 55.77, P/S 8.42) against impressive profitability (ROE 43.94%, net margin 15.09%), while analyst consensus remains overwhelmingly bullish with a $364.94 price target. Recent news highlights Vertiv's strategic positioning in AI infrastructure cooling solutions.
Outlook remains positive given Vertiv's exposure to the $7.6 trillion AI spending boom (Goldman Sachs, Sep 2026), though risks include potential securities law investigations and competitive pressures. The stock offers growth exposure to data center electrification trends, with Q3 2026 earnings (expected EPS $1.82) serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
